Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information and Holders of Record
Our common stock trades on the Nasdaq Global Select Market, or Nasdaq, under the symbol "PGEN".
As of February 15, 2026, we had 271 holders of record of our common stock. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include shareholders whose shares may be held in trust by other entities.
Dividends
We have never declared or paid any cash dividends on our capital stock. We currently intend to retain earnings, if any, to finance the growth and development of our business and do not expect to pay any cash dividends on our common stock in the foreseeable future.
Securities Authorized for Issuance under Equity Compensation Plans
Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.
Stock Performance Graph
This performance graph shall not be deemed "soliciting material" or to be "filed" with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Precigen, Inc. under the Securities Act of 1933, as amended, or the Exchange Act.
The following graph shows a comparison from December 31, 2020, through December 31, 2025 of the cumulative total return for our common stock; the Standard & Poor's 500 Stock Index, or the S&P 500 Index; and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested at the market close on December 31, 2020, in the common stock of Precigen, Inc., the S&P 500 Index, and the Nasdaq Biotechnology Index, and data for the S&P 500 Index and the Nasdaq Biotechnology Index assumes reinvestments of dividends. The stock price performance of the following graph is not necessarily indicative of future stock price performance.
71
Table of Contents
Company / Index Base Period 12/31/2020 3/31/2021 6/30/2021 9/30/2021 12/31/2021
Precigen, Inc. $ 100.00 $ 67.55 $ 63.92 $ 48.92 $ 36.37
S&P 500 Index 100.00 106.17 115.25 115.92 128.71
N asdaq Biotechnology Index
100.00 99.28 108.17 106.85 99.37
Company / Index 3/31/2022 6/30/2022 9/30/2022 12/30/2022 3/31/2023 6/30/2023 9/29/2023 12/29/2023
Precigen, Inc. $ 20.69 $ 13.14 $ 20.78 $ 14.90 $ 10.39 $ 11.27 $ 13.92 $ 13.14
S&P 500 Index 122.79 103.02 97.99 105.40 113.30 123.20 119.17 133.10
Nasdaq Biotechnology Index 87.54 78.77 79.17 88.53 86.68 85.67 83.07 91.84
Company / Index 3/29/2024 6/28/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Precigen, Inc. $ 14.22 $ 15.49 $ 9.29 $ 10.98 $ 14.61 $ 13.92 $ 32.25 $ 40.98
S&P 500 Index 147.15 153.46 162.49 166.40 159.29 176.72 191.08 196.16
Nasdaq Biotechnology Index 93.08 95.51 100.18 90.58 89.18 88.83 102.54 119.92
Recent Sales of Unregistered Securities and Use of Proceeds from Registered Securities
(a) Sales of Unregistered Securities
On September 15, 2025, the holders of Precigen, Inc.’s 8.00% Series A Convertible Perpetual Preferred Stock (“Preferred Stock”) converted 79,000 shares of Preferred Stock (with an aggregate stated value of $79.0 million) into 54,937,411 shares of
72
Table of Contents
common stock of the Company, which were delivered to such holders on September 17, 2025 pursuant to the terms of our Amended and Restated Articles of Incorporation and such Preferred Stock at the then-current conversion rate of 695.4103 shares of our common stock per $1,000 of stated value of Preferred Stock.
The shares of our common stock issued upon conversion of the Preferred Stock were issued in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended, as involving an exchange by us exclusively with our existing security holders in a transaction where no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange.
(b) Use of Proceeds
None.
(c) Issuer Repurchases of Equity Securities
None.
Item 6. [Reserved]